Lastly, MH84 a PPAR-γ agonist/γ-secretase modulator, reduced Aβ42 in HEK293APPwt cells, characterized by elevated Aβ42 levels, and improved mitochondrial dysfunction (Pohland et al., 2016), thus performing in vivo MH84 studies applied to AD therapy may be worth. Here, PPARG is linked to Alzheimer disease.